Literature DB >> 17150260

Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.

Brandon T Larsen1, William B Campbell, David D Gutterman.   

Abstract

Epoxyeicosatrienoic acids (EETs), derived from arachidonic acid by cytochrome P450 epoxygenases, are potent vasodilators that function as endothelium-derived hyperpolarizing factors in some vascular beds. EETs are rapidly metabolized by soluble epoxide hydrolase to form dihydroxyeicosatrienoic acids (DHETs). Recent reports indicate that EETs have several important non-vasomotor regulatory roles in the cardiovascular system. EETs are potent anti-inflammatory agents and might function as endogenous anti-atherogenic compounds. In addition, EETs and DHETs might stimulate lipid metabolism and regulate insulin sensitivity. Thus, pharmacological inhibition of soluble epoxide hydrolase might be useful not only for hypertension but also for abating atherosclerosis, diabetes mellitus and the metabolic syndrome. Finally, although usually protective in the systemic circulation, EETs might adversely affect the pulmonary circulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150260     DOI: 10.1016/j.tips.2006.11.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  42 in total

1.  11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries.

Authors:  Ishfaq A Bukhari; Abdul Jabbar Shah; Kathryn M Gauthier; Katherine A Walsh; Sreenivasulu Reddy Koduru; John D Imig; John R Falck; William B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

3.  Reduced flow-and acetylcholine-induced dilations in visceral compared to subcutaneous adipose arterioles in human morbid obesity.

Authors:  Ivana Grizelj; Ana Cavka; Jing-Tan Bian; Mary Szczurek; Austin Robinson; Shruti Shinde; Van Nguyen; Carol Braunschweig; Edward Wang; Ines Drenjancevic; Shane A Phillips
Journal:  Microcirculation       Date:  2015-01       Impact factor: 2.628

4.  Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

Authors:  Eric A Evangelista; Rüdiger Kaspera; Nahush A Mokadam; J P Jones; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2013-09-10       Impact factor: 3.922

Review 5.  Arachidonic acid and ion channels: an update.

Authors:  H Meves
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

Review 6.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

Review 7.  Arachidonic acid cytochrome P450 epoxygenase pathway.

Authors:  Arthur A Spector
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

8.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

9.  Mitochondrial P450-dependent arachidonic acid metabolism by TCDD-induced hepatic CYP1A5; conversion of EETs to DHETs by mitochondrial soluble epoxide hydrolase.

Authors:  Erin M Labitzke; Silvia Diani-Moore; Arleen B Rifkind
Journal:  Arch Biochem Biophys       Date:  2007-08-25       Impact factor: 4.013

10.  Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species.

Authors:  Brandon T Larsen; Aaron H Bubolz; Suelhem A Mendoza; Kirkwood A Pritchard; David D Gutterman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-02-12       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.